Mathematical modelling of tumour development during angiogenesis and treatment by anti-angiogenesis. by Rasenyalo, Nonduduzo Maureen.
MATHEMATICAL MODELLING OF TUMOUR
DEVELOPMENT DURING ANGIOGENESIS AND
TREATMENT BY ANTI-ANGIOGENESIS
A DISSERTATION SUBMITTED TO THE UNIVERSITY OF KWAZULU-NATAL
FOR THE DEGREE OF MASTER OF SCIENCE
IN THE COLLEGE OF AGRICULTURE, ENGINEERING & SCIENCE
By
Nonduduzo Maureen Rasenyalo
School of Mathematics, Statistics & Computer Science
June 2016
Abstract
The study focuses on mathematical modelling of tumour development during angiogenesis.
It is the stage during which the tumour changes from being avascular to vascular. During
this process the tumour secretes tumour angiogenetic factors which diffuse to surrounding
tissues. As a result endothelial cells lining nearby blood vessels are stimulated and begin to
degrade their basement membrane. Endothelial cells also excrete a chemical, fibronectin,
which helps to stick cells together. Then, endothelial cells migrate towards the tumour
through diffusion, chemotaxis, haptotaxis and proliferation and they then form small cap-
illary sprouts. These sprouts with time, grow and form loops, and thus, allow a blood
circulation. This process of sprout growth, extension and loop formation continue until
the capillaries eventually reach and penetrate the tumour, thus completing the angiogenetic
process. This formation of new blood vessels is known as angiogenesis.
In this study we present two mathematical models. The first model of nonlinear partial
differential equations describing the interactions between endothelial cells, fibronectin and
tumour angiogenetic factors in the development of new blood vessels. The model describe
the initial migratory response of each cell population in the process during which the tu-
mour acquires its own blood supply. The model aim to capture the spatial distribution of
endothelial cells through diffusion, chemotaxis, haptotaxis, proliferation and cell loss due
to decay .
The second model focuses on the treatment of tumour by introducing anti-angiogenetic
i
treatment. During this process chemicals, namely the tumour angiogenetic factors secreted
by the tumour and anti-angiogenetic factors which is added as a treatment are seen to be
opposing each other.
The continuous equations obtained are solved using the Crank-Nicolson method. The re-
sults showed that with time, the tumour angiogenectic factor decreases from the tumour
and the endothelial cells migrate towards the tumour. When the anti-angiogenetic factor is
added, the angiogenesis process is hindered. Results showed that the secretion of tumour
angiogenetic factor by tumour is hindered and also that the presence of endothelial cells in
the arbitrary region diminishes.
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Cancer is a life threatening disease of epidemic proportions. World Cancer Report [1]
highlighted that trends in cancer incidence and mortality worldwide is growing rapidly. It
highlighted that in 2012 the world wide burden of cancer rose to an estimated fourteen
million new cases per year and the figure is expected to rise to upto twenty two million
annually within the next twenty years. Over the same period, cancer deaths are predicted
to rise from an estimated 8.2 million annually to 13 million per year. The report indicated
that they is a need for a speedy implementation of efficient prevention strategies.
The epidemic results from uncontrollable division of tumour cells with sustaining blood
supply. The tumour may result from errors in cell division leading gradually to cells that
are more and more abnormal. However if they survive, the damaged cells can continue to
divide.[2, 3]. A tumour may also be caused by damage to the cells′ in the deoxyribonucleic
acid, through environmental exposures, as from chemicals in tobacco smoke (leading to
lung cancer) or ultraviolet radiation(leading to skin cancer)[4, 5]. Peterson [5] argued that
tobacco consumption has also been implicated as the cause for cancers of the following:
1
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oral cavity, pharynx, larynx, oesophagus, stomach, pancreas, liver, kidney, ureter, urinary
bladder, uterine cervix and bone marrow (myeloid leukaemia).
The success of a tumour treatment depends on it being appropriate for the type of tumour
involved. Therefore it is necessary to understand the different forms of tumours, and the
processes and stages involved in their development and growth [6, 7, 8].
In this dissertation mathematical models will be used to gain insight into the processes of
anti-angiogenesis, and its use in treating cancer. To this end, the next section will give an
overview of the development of tumours; types of tumours that occur and the stages in
tumour growth, namely angiogenesis and metastasis. Then some cancer treatment strate-
gies are outlined, focusing on anti-angiogenesis. This is followed by a section that outlines
some mathematical models used to describe these processes. Finally the study aims are
given, together with an overview of the remainder of the dissertation.
1.2 Stages of Tumour Development
Tumour develop in three main phases, the avascular phase(benign), the vascular phase and
the malignant phase(cancer) [9]. The stages are illustrated in Figure 1.1, and are described
below. A tumour in the avascular phase is non cancerous(benign). When such a tumour
is less than about two millimeters in diameter, it is unlikely to be harmful; it will only
cause serious health problems if it grows in a critical body organ, or if it becomes too
large. However without its own blood vessels, its survival, depends on diffusion for oxygen
and nutrients from nearby blood vessels and for removal of waste products to these blood
vessels [11, 12]. So at this stage, a tumour usually develops very slowly and does not
proliferate or spread to other tissues or organs. In this early stage a tumour can usually be
removed or be treated with radiation [4]. When removed, benign tumours do not usually
regrow [9]. However, if they are not treated or removed at this stage, they may develop into
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Figure 1.1: Diagram Showing Solid Tumour Development [10]
cancer. After reaching its maximal diameter of about three millimeters, the second stage of
the tumour development is observed, called angiogenesis[13, 11, 14, 15].
Angiogenesis is the transition stage in which a tumour develops its own blood supply. In
other words it changes from being avascular (pre-malignantor benign) to vascular (malig-
nant) [16].
Angiogenesis may be explained as the process of tumour development, occuring between
the harmless avascular growth phase and the of vascular growth [11, 14, 17, 18]. Ander-
son et al. [17] maintain that angiogenesis is a process that starts only when the tumour
secretes several chemicals, collectively called tumour angiogenic factors (TAFs). During
angiogenesis, the tumour angiogenic factors diffuse through the tissues, creating a chem-
ical gradient between the tumour and blood vessels [18]. When these chemicals reach a
neighbouring blood vessel, endothelial cells that line the blood vessel have a chemotactic
response and secrete an enzyme that degrades the basement membrane , which was holding
them in place. Once the basement membrane is degraded then endothelial cells are free to
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migrates towards the tumour. They proliferate and form capillary sprouts, which are shown
in Figure 1.1 after 6 days as finger-like extensions . Following the leading endothelial cell
at a sprout tip, the sprouts can develop further into loops, called (anastomoses) and thus,
permit a primitive blood circulation, see Figure 1.1 after 8 days. The processes of sprout
growth, extension (through endothelial cell migration and proliferation), and loop forma-
tion continues until the capillaries so formed eventually reach and penetrate the tumour,
thus completing the angiogenic process [10].
Alongside cells proliferation, the endothelial cells also secrete fibronectin; a chemical that
remains bound to the extracellular matrix creating a concentration gradient. According to
Anderson [19], extra cellular matrix is a mixture of macromolecules, like the collagens,
laminin, fibronectin and vitronectin, which are important for cell adhesion, spreading and
motility. Fibronectin allows endothelial cells to adhere to the extracellular matrix and so
promotes cell proliferation up the concentration gradient. This response of endothelial cells
to fibronectin is commonly called haptotaxis [14, 18, 20, 21].
Once the capilliary sprouts reach the tumour, vascularization begins, whereby the tumour
forms its own blood vessels. Now the tumour is regarded as malignant because it has
reached. a cancerous stage. Malignant tumours vary in size and shape. With an unlimited
supply of nutrients via its own blood vessels, tumour growth can be uncontrollable. During
this stage cancer cells also move away from the original tumour, or primary cancer. This
process of tumour development, called metastasis, occurs as cells migrate, through the
blood or lymph system and form new tumours (metastatic tumours). A metastatic tumour
is thus the same type as the primary tumuor [4, 9]. Malignant tumours thus interfere with
body functions and become life-threatening. Surgical and radiation treatment options are
more limited, and may have less successful outcomes [4].
Consequently,this dissertation focuses on mathematical modelling of the critical stage of
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Figure 1.2: An Illustration of the spread of cancer :Source [22]
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angiogenesis. It will show how the process can be inhibited before the cancer can cause life-
threatening complications. When one understands tumour development, then it becomes
easier to decide on appropriate treatment.
1.3 Tumour Treatment
As has been argued above, angiogenesis is a critical process in cancer development. But its
complexity makes it difficulty to develop an effective treatment for it [4]. Billy et al. [23]
have motivated for efforts to be directed towards identifying inhibitors of this process. Most
patients with cancer receive surgery, chemotherapy, radiation therapy, or other conventional
therapies or a combination as a form of treatment.
Cancer cells reproduce by dividing rapidly, and this attribute is targeted in conventional
chemotherapeutic treatment. However, as Sanga et al. [4] note, some normal body cells
are also dividing rapidly. The challenge with chemotherapy is that cancer cells are not
like bacteria, so it becomes hard to eliminate them without also affecting some of healthy
rapidly-reproducing cells. Thus chemotherapy will kill other cells, like cells in, hair fol-
licles, gastrointestinal tract, bone marrow, and mucous membranes. That is why some
patients experience side effects when undergoing chemotherapy such as loss of hair , nau-
sea, ulcers, and mouth ulcers. Nevertheless, healthy cells can more easily repair themselves
than can cancer cells [24].
Other treatment strategies are described by Sanga et al. [4]. The aim of the neovasculature
strategy is to destroy a tumour′s source of oxygen and nutrients, so as to starve it. Sanga
et al. [4] mention a method called vascular normalization, whose aim to normalize the
abnormal structure and function of tumour vasculature and to improve the delivery of oxy-
gen, nutrients and drugs . Another possible treatment involves the nanovectored therapy,
whereby nanoscale devices are employed to deliver drug payloads to cancer cells [4].
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Another strategy to treat cancer involves anti-angiogenesis. This approach harnesses a nat-
urally occurring process in tumour development and uses it to inhibit tumour angiogenesis.
Anti-angiogenesis was demonstrated in experiments with mice. Folkman [13], Anderson et
al. [17] discussed an experiment on mice where numerous types of tumour were implanted
in mice and were allowed to grow. The mice were then checked for the presence of sec-
ondary tumour, in particular in the lungs and results indicated little or no evidence of the
presence of secondary tumour. However, upon removal of the primary tumour, rapid growth
of the hidden micro-metastases were observed, leading to the growth of many large sec-
ondary tumours. They concluded that primary tumour secretes substances that inhibit an-
giogenesis, so-called anti-angiogenic factors. As the primary tumour is fully vascularised,
these anti-angiogenic factors are transported through tissues surrounding blood vessel into
the blood stream, and therefore, may hinders angiogenesis of the secondary tumour. They
observed that the growth of new capillary sprout is promoted by a diffusible factor gener-
ated by primary tumour cells. They also added that in the absence of neovascularization
most tumours might become dormant if they remain small; at a diameter, of about 2 to 3
mm.
Levine et al. [20] describe anti-angiogenesis as a process whereby anti-angiogenic factors
(AAF) are applied to hinder the development of a tumour. Similarly Ledzewicz and Schat-
tler [25] explained anti-angiogenesis as a cancer treatment that aims to hinder a tumuor
vascularization. Anderson et al. [17] consider anti-angiogenesis to be a ′normal′ tumour in-
duced process. Specifically, they defined anti-angiogenesis as the process whereby growth
of endothelial cells is hindered by the anti-angiogenic factor produced by primary tumour.
In the same vein, Levine et al., Ledzewicz and Schattler [20, 25] and Rabii et al. [26] point
out the two-way nature of processes occurring between tumour angiogeniic factor and en-
dothelial cells. On the one hand, tumour cells produce a vascular endothelial growth factor
to stimulate endothelial cell growth whereas on the other hand endothelial cells also have
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receptors which make them sensitive to inhibitors of angiogenesis, called anti-angiostatin.
This chemical thus reduce the development of new endothelial cells and capillaries and
so hinders the growth of endothelial cells. The Endothelial cells of the secondary tumour
thus respond chemotatically to two opposing chemical gradients in the surrounding tissue
or extracellular matrix. In one direction, the concentration of tumour angiogenic factors,
which are cytokines secreted by the secondary tumour, drive the angiogenesis process as
described above. In the opposing direction there is the concentration of anti-angiogenic
factors secreted by the primary tumour.
Orme and Chaplain [12] presented three different methods of using anti-angiogenesis in
cancer treatment. One is cytotoxic treatment, which targets and destroys endothelial cells.
This therapy is most beneficial if pre-existing blood vessels can be left unaffected. Another
treatment uses inhibitation of mitosis(cell division). The third option prevent endothelial
cell migration.
Cancer therapies are constantly changing. Developments in science and technology allow
new treatments, that are more effective, and with harmful side effects. For example, ad-
vances such as tomotherapy allow for the treatment of tumours in areas that might not oth-
erwise withstand further radiation [24]. New treatment options can be evaluated in clinical
trials, but may also be explored through mathematical modelling, with no risk to patients.
This is discussed in the next section. Mathematical models can even be used to develop
patient-specific therapeutic schemes [4].
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1.4 Role of Mathematical Modelling in Tumour Develop-
ment
Mathematical modelling and computer simulations have proved to be useful tools for un-
derstanding tumour development and cancer treatment. The application of numerical meth-
ods has been facilitated by modern high speed computers[27, 28]. Computer simulations
can provide valuable information into the processes of tumour development and provide a
platform for analyzing the effectiveness of therapeutic treatment [4]. Sanga et.al [4]also
suggest that mathematical modelling can be integrated with other tools, such as biologi-
cal experiments, clinical trials and computer simulation to provide a good comprehensive
framework for understanding tumour development and its response to treatments. They
point out that traditional clinical or biological experiments are costly and subject to human
error. Furthermore, experiments that can be run computationally through mathematical
models have been difficult or impossible empirically. These models can also be invaluable
in planning suitable biological experiments to test theoretical hypotheses. Nevertheless
solving the equations in the models requires empirical biological data appropriate for the
model constraints and parameters. Therefore modelling and practical experiments comple-
ment each other.
The importance of endothelial cell proliferation has been shown in earlier sections to be
critical in tumour development. Various mathematical models have been developed for en-
dothelial cells growth during different tumour development stages. In the following section
previously published models governing tumour development will be discussed.
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1.5 Review of Mathematical Models for Tumour
Several mathematical models for tumour development have been formulated; many focus-
ing on specific cancer phases (that is, avascular, angiogenesis or vascular). The models can
be categorized as either continuum or a discrete, or a hybrid of the two. Continuum models
draw upon principles of fluid and continuum mechanics and they use differential equations
to describe cancer related variables as continuous variables [4]. On the other hand, discrete
models are used in cellular automation, which are governed by a set of rules that are de-
terministic or probabilistic or both. The state of discrete of these elements can be tracked
through both space and time [4]. Hybrid cancer modelling approaches combine continuum
models with discrete models [4]. Models that will be formulated in this dissertation are
discrete in nature.
1.5.1 Avascular Tumour Models
For tumour growth during the avascular stage, Ward and King [2]. formulated a model
based on a continuum phase of cells in two states, living or dead. In the living state,
cells are assumed to be able to expand, due to cell production and proliferation, at a rate
that is dependent on the concentration of nutrient. Cell death is an irreversible transition
that is assumed to cause a spontaneous loss of cells. The reaction diffusion equations
governing the living and dead cell concentrations, in relation to the local velocity of cells,
are formulated. The rate of transition of living cells is determined by the difference in the
rates of mitosis and death of the cells.
Section 1.5. Review of Mathematical Models for Tumour Page 11
1.5.2 Angiogenesis Tumour Models
Several models for angiogenesis have been published. Anderson and Chaplain and Stephanou
et al. [11, 15] considered a one-dimensional model for capillary sprout formation in the ab-
sence of mitosis of endothelial-cell. They assumed that the movement of endothelial cells
is influenced by three factors: random motility i.e molecular diffusion , chemotaxis in
response to tumour angiogenic factor gradients haptotaxis in response to fibronectin gra-
dients. Holmes and Sleeman [29] developed a model for the conservation of endothelial
cells. The equation includes terms for mitosis, which is governed by logistic growth and
depends on the level of tumour angiogenic factor. Eloundou [30] also formulated a con-
servation equation for endothelial cells development. This model differs from the earlier
models because it does not include the term for haptotaxis, but instead included the a term
for cell loss due to death.
1.5.3 Metastasis Tumour Models
Metastasis occurs when cancer cells migrate from the primary tumour to other organs where
they form new (secondary) tumours. According to Franziska et al. [31] and Chaplain et
al. [10], metastasis is a complex process that involvinges a series of steps. Initially tumour
cells detach themselves from the primary tumour and then they attach to the neighbouring
extracellular matrix, which separates the initially tumour and from adjoining tissues. When
tumour cells reach the extracellular matrix, they secrete enzymes, that degrade the proteins
that bind them with the extracellular matrix. Tumour cells are then able to breach the ex-
tracellular matrix and escape into the neighbouring tissue. Their movement is enhanced by
adhesion and proliferation. They spread either by direct extension into adjacent tissues, or
through the circulatory system, via lymphatic or blood vessels. The last stage of metas-
tasizing is arrest or extravasion. From the circulatory system, mobile tumour cells come
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to rest at another site, where they then grow and multiply. When the angiogenesis pro-
cess starts again, secondary, cancer cells continue to expand, eventually forming another
tumours. This new tumour is known as a metastatic or secondary tumour.
When modelling metastasis, Chaplain et al. [32], Anderson et.al [33] consider tumour cells,
the extracellular matrix and matrix degradation enzymes. In both publications, the authors
assumed that the model the tumour cell development is governed only by diffusion and
haptotaxis, because matrix degradation enzymes can degrade the matrix only upon contact,
which Anderson [19] points out is a critical part of the metastatic process. While the
active matrix degradation enzymes are secreted by the tumour cells, they also decay as they
diffuse through the tissue. In addition, Chaplain et al. [32] added a term for endothelial cell
proliferation, They also highlight that endothelial cell movement is governed by diffusion,
as well as cell to cell adhesion and cell to matrix adhesion.
The model governing cell invasion formulated by Eleondou [30] did not include haptotaxis.
Nevertheless, the author indicates that during invasion under some conditions, tumour cell
proliferation may be suppressed by competition for nutrients, oxygen and space. Thus,
cells in the interior of the tumour do not proliferate as quickly as those on the surface.
Anderson et al. [17] focused on four key variables involved in cancer cell invasion; which
are, cancer cell density, matrix degradation enzyme concentration, macromolecular concen-
tration and oxygen concentration. Each of these four variables is a function of the spatial
variable x and time t. Oxygen diffuses among the macromolecules, where it is consumed
by the tumour, so its concentration is assumed to decay naturally.
1.5.4 Anti-angiogenesis Tumour Models
Besides the experimental evidence, Anderson et al. [17] argued that the dose-dependent
method also confirmed that anti-angiogenic factors (such as angiostatin and endostatin)
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hinders the growth of endothelial cells. Anderson et al. [17] and Collins [21] pointed out
that endothelial cell migration is governed by two opposing chemicals that is a chemotatic
response due to tumour angiogenetic factors and a hindrance of endothelial cells growth
due to angiostatin.
The model developed by Anderson et al. [17] considered endothelial cell movement to be
governed by a chemotatic response to tumour angiogenic factors and by anti-angiogenesis.
The endothelial cells respond to angiostatin gradients in a dose dependent method describ-
ing cell migration.
This study will therefore strengthen models developed for angiogenesis by including terms
for anti-angiogenesis. To be specific, in this dissertation a mathematical model of angio-
genesis process will first be formulated, based on endothelial cells, tumour angiogenic fac-
tors and fibronectin. The equations in the model will be solved using the Crank-Nicolson
scheme, then the model will be simulated using Matlab software.
From the angiogenesis model, a term for the anti-angiogenic factor that hinders tumour
growth will be introduced. The anti-angiogenesis model will then be simulated with Matlab
aiming to observe the tumour growth in relation to anti-angiogenetic factor therapy.
1.6 An Overview of the Dissertation
This dissertation is presented as follows: Chapter 1 has shown the different stages of can-
cer tumour development and some methods of cancer treatment that are available. Math-
ematical models formulated for avascular tumours, angiogenesis , metastasis and anti-
angiogenesis were discussed. Chapter 2 will discuss the Crank-Nicolson method, which
will be used to solve the Finite Difference scheme that arises from models formulated in
this dissertation. Chapter 3 will present mathematical models describing the process of
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angiogenesis, namely, focusing on the tumour angiogenic factor, fibronectin and endothe-
lial cell concentration. After the application of Crank-Nicolson ′ method, solutions of the
equations from model simulation with Matlab will be presented. In Chapter4 anti - an-
giogenesis will be considered. An anti-angiogenic factor will be added to the equation for
endothelial cell that has been formulated in Chapter 3. The governing equations for anti-
angiogenesis will also be solved and results will be presented. Chapter 5 will presents the
summary of all work done, conclusion and future research prospects.
1.7 Summary
Tumours can be classified into three stages: avascular, vascular and malignant. During
the early avascular stages most tumours are harmless or can be treated successfully. But
not early enough a tumour progress to malignancy, known as cancer. This critical stage
in the tumour development depends on the tumour becoming vascular by the process of
angiogenesis. Once tumour reaches vascular stage, it starts mestasise and invade to other
parts of the body. It is important that proper treatment is administered as early as one
discover the sickness. Anti-angiogenesis is also one of the methods that can be employed
to treat cancer. The method assist to hinder the tumour growth.
Mathematical models have been formulated for different stages of tumour development.
Such models can provide valuable information, which can be used to plan physical experi-
ments including those concerning treatment therapies. Symbiotically, data from biological
experiments also provide the necessary parametric values needed in the models. Thus
mathematical modelling makes an important contribution to biological knowledge. Be-
cause of complexity of equations in such mathematical models, numerical methods such as
the Crank-Nicolson method, and computational simulations are valuable in analyzing and
solving them.
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Models for avascular tumours and angiogenesis have been established. However there is
little work done on including terms for anti-angiogenesis. Addressing this deficit will be the
focus of the dissertation. In the next Chapter the Finite Difference scheme and the Crank-
Nicolson′s method, which will be used to solve equations in the models to be formulated




This chapter will present the two types of numerical methods, the spectral local lineariza-
tion method and finite difference method. Both methods could be applied to solve equations
in models that will be generated in this dissertation although we have decided to use the
finite difference scheme because of the low number of boundary conditions. The Crank-
Nicolson method will also be discussed as it is an appropriate finite difference scheme for
the models in this dissertation. The Crank-Nicholson method has proved itself to be a uni-
versal and stable numerical scheme . After applying the Crank-Nicolson scheme, systems
of linear equations that will be generated for each row will be expressed as a matrix equa-
tion. A brief summary of matrices will be presented and resulting matrix equation will be
simulated using Matlab software.
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2.2 Numerical Methods
Choice of partial difference scheme depends on the partial differential equation that is re-
quired to be solved. Partial differential equations fall into three categories, that is elliptic,
parabolic and hyperbolic. Not all partial differential equations can be solved analytically
but numerical methods can be used to give approximate solutions [35]. Ozisik [28] points
out that numerical methods are useful for solving complicated nonlinear problems with
complicated boundary conditions. Finite difference methods are used worldwide in solv-
ing equations related to heat, mass and momentum transfer and each method has its own
advantages depending on the nature of the problem but there is no single method that is best
for all nonlinear partial differential equations [28]. According to Motsa et al. [27], methods
have been developed to find efficient ways to solve such equations, the spectral local lin-
earization method and finite difference method being amongst them. This dissertation will
touch on the spectral local linearization method but discuss the finite difference method in
depth because it will be used to solve the system of equations that will be generated in this
study.
2.2.1 Spectral Local Linearization Method
One of the simplest and efficient method for solving highly nonlinear systems of boundary
layer flow problems with exponentially decaying profiles is the spectral local linearization
method (SLLM).The method is based on linearizing and decoupling systems of equations
using a combination of a univariate linearization technique and a spectral collocation dis-
cretization [27, 34]. The governing systems of equations are reduced into a sequence of
subsystems of differential equations. After linearizing them, they are then solved using a
pseudo Chebyshev pseudospectral method. The method has proved to converge rapidly so
obtains results very efficientlly. Its level of accuracy is very high especially when solving
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Figure 2.1: Computational Grid Showing Interior Grid Points
very large nonlinear boundary value problems. [27, 34].
2.2.2 Finite Difference Methods






, 0 ≤ x ≤ L, t ≥ 0, (2.1)
where θ = θ(x, t) is a dependent variable and α is a constant co-efficient. Recktenwald [36]
applies a finite difference method, as follows to solve equation(2.1) at any point (x0, t0),
the numeral scheme is restricted to the points on the grid of discrete x values as illustrated
in Figure 2.1[37]. Assume that the domain is rectangular with x, distance ranging from 0 to
X and t, time ranging from 0 to T . The interval [0, X] is divided into N equal subintervals
of length δx. The x values are indexed by i = 0, ..., N . Similarly the interval [0, T ] is
divided into M equal intervals of length δt and with t values indexed by j = 0, ...,M . The
aim is to find an approximation for the values of θ at (N + 1) × (M + 1) grid points
[37, 38]. The solution for equation (2.1) requires specified boundary conditions at x = 0
and x = L, and initial conditions at t = 0, as θ(0, t) = θ0, θ(L, t) = θL and θ(x, 0) = f0(x)
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[36].
Recktenwald [36] and Strikwerda [38] both point out that finite difference methods are ob-
tained by replacing continuous derivatives with difference formulae that involves several
discrete approximations given by the numerical solution at a finite number of points in the
physical domain. Figure 2.1 is a schematic representation of the numerical solution, where,
∆x, the local distance between adjacent points in space, and ∆t, the local distance between
adjacent time steps are both uniform throughout the mesh [36]. Thus, Figure 2.1 illustrates
the region over which the independent variables in the partial differential equation are de-
fined, by a finite grid of points, or a mesh, where each dependent variable is approximated.
In the heat equation there are derivatives with respect to time, and derivatives with respect
to space. Various combinations of mesh points, in the difference formulae, results in a
variety of schemes.
In a finite difference method each partial derivative in the partial differential equation is
approximated from neighbouring values using Taylor’s theorem [35]. Using first order
partial derivative in Taylor’s theorem [35], we let:








3) + · · · , (2.2)
From the Taylor series the derivative, a′(x) will be
a′(x0) =







a′′′(x0) + · · · . (2.3)
Equation (2.3) contains an unknown quantity, 0(h3) . If all terms with that quantity are
discarded in Equation (2.3), then the approximation for a′(x0) becomes
a′(x0) ≈
a(x0 + h)− a(x0)
h
, (2.4)
, for a small value of h. Equation (2.4) is called the forward divided difference, with the
error of 0(h3) From Equation (2.3) if h is substituted with −h then:
a′(x0) ≈
a(x0)− a(x0 − h)
h
, (2.5)
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for a small value of h. equation (2.5) is called the backward divided difference. The central
difference approximations of a′(x): is obtained by adding equations (2.4) and (2.5) and it
becomes:
a′(x0) ≈
a(x0 + h)− a(x0 − h)
2h
, (2.6)
for a small value of h, with an error of the order h2.
The second order central difference approximations can be obtained with the additional
manipulations of the Taylor series expansion as it appears in equation (2.2) and making




[a(x0 + h)− a(x0)− ha′(x0)]. (2.7)




[a(x0 − h)− a(x0) + ha′(x0)]. (2.8)
By adding equations and , then the central difference approximation becomes:
a′′(x0) ≈
a(x0 + h)− 2a(x0) + a(x0 − h)
h2
, (2.9)
[35, 39]. In a finite difference scheme the points x0 and x0 + h are points on the grid and
a(x0) and the value of a(x0 + h) are known. Then using equation (2.3) allows one to get
the finite difference approximation to derivatives with O(hn) errors.
If one lets a be a function of two variables t and x, then one can approximate derivatives
of a with respect to x0. If t is held constant then Taylor’s theorem in equation (2.2) can be
used where a simple derivative terms is changed to a partial derivative. If h is replaced by
δx, then equation (2.2) can be written as:













+· · · . (2.10)
On Truncation equation (2.10) yields :
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First Order Forward Difference Approximation
Re - arranging Equation (2.11) allows us to obtain the forward and backward finite differ-
ence approximations to the partial derivatives as shown below:
∂a(t, x0)
∂x
≈ a(t, x0 + δx)− a(t, x0)
δx
+O(δx), (2.12)
and the approximation error is O(δx) and that leads to:
∂a(t, x0)
∂x












, where aji+1 = a(tj, xi+1) ana a
j
i = a(tj, xi. Equation (2.14) is called the first order
forward difference approximation to ∂a(tj ,xi)
∂x
,
First Order Backward Difference Approximation












First Order Central Approximation
The first order central difference approximation to a(tj, xi) is obtained by adding equations









Higher order partial derivatives approximations can also be made by taking more terms in
Taylor’s theorem.
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Second Order Finite Difference Approximation















and if (δx) is replaced by −(δx)















Adding equation (2.17) and equation (2.18)

























Table 2.1: Finite Difference Toolkit






























































central first in t
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There are various methods of attaining numerical solutions to partial differential equations
each with relation to the kind of problem that is required to be solved as indicated on
the Table 2.1 [35]. The most common finite difference methods are the explicit method,
implicit method and Crank-Nicolson Method. These methods are closely related but differ
in stability, accuracy and in speed of execution [28, 36, 39].
2.3 The Crank-Nicolson Method
A method for getting the value of uj+1i in parabolic partial differential equations was for-


























Then Figure 2.2, illustrates the Crank-Nicolson schemes, which is the average of the for-
ward method at j and the backward method at j + 1 as given in equation (2.23)
There are implicit and explicit Crank-Nicolson scheme. In this dissertation the implicit
scheme will be used. The implicit Crank-Nicolson scheme is a highly recommended, stable
method, for steps δx in position and δt in time. Errors are of order (δx)4 and order (δt)2
respectively.
According to Eloundou [30] to get the next value of u in time using the implicit method,







are approximated as follows:
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Figure 2.2: An illustration of the Crank-Nicolson Method
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Table 2.2: Finite Difference Toolkit






























































central first in t
2.3.1 Unconditional Stability of the Crank-Nicolson Method
The Crank-Nicolson Method has been proved to be stable and reliable. Its stability has






, t > 0, x ∈ (0, L), (2.24)
is a parabolic equation, with Diriclet boundary conditions a(0, t) = u1(t), a(L, t) = u2(t)
and initial conditions a(x, 0) = a0(x). Then if one discretizes space by h such that (n +
1)h = 0, n ∈ N, and h > 0. Using Table 2.2 above and substituting for the first order
forward derivative in relation to t in ∂a
∂t























If we let α = δt
(δx)2
and substitute in equation (2.36), then equation (2.36) can be written as:











Which can be expressed as:
− α(aj+1i−1 + a
j+1






i+1 ) + 2(1− α)a
j+1
i . (2.27)
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equation (2.27) results in a matrix of the form Aaj+1i = Ba
j
i , j = 0, 1, · · · .
Faduga et al. [39] considered the worst case solution of equation (2.27) by letting
aji = ρ
j(−1)i. (2.28)
To prove unconditional stability of the Crank Nicholson scheme, we need to show that
|ρ| < 1.
Substituting equation (2.28) into equation (2.27) we get:
−α(ρ)j+1(−1)i−1((−1)i+1 + (−1)i−1) + 2(1 + α)(ρ)j+1(−1)i
= α(ρ)j(−1)i−1((−1)i+1 + (−1)i−1) + 2(1 + α)(ρ)j(−1)i. (2.29)
Equation (2.30) results to:
ρ[−α(−1)− 1 + 2(1 + α)− α(−1) + 1] = α(−1)− 1 + 2(1− α) + α(−1) + 1. (2.30)





then we can conclude by:
ρ = |1− 2α
1 + 2α
| =⇒ |ρ| < 1 ∀ ρ > 0 (2.32)
The denominator is always positive, while the numerator may be positive or negative. In
any case, it is clear that the absolute value of the numerator is smaller than the denomina-
tor,which means that |ρ| < 1 and that completes the proof.
The conclusion indicates that the Crank-Nicolson Method is unconditionally stable and has
a very high order of accuracy. As mentioned earlier, it is commonly used in solving heat
equations [39].
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2.3.2 Application of the Crank-Nicolson Method in Nonlinear Parabolic
Partial Differential Equations
Suppose we need the solution of equation (2.1) which is a one space dimensional system
of equation as x is the only independent spatial variable involved, based on the following
boundary conditions:
θ(0, t) = 0, θ(L, t) = 0, 0 ≤ t ≤ T, (2.33)
and the initial conditions:
θ(x, 0) = f(x), 0 ≤ x ≤ L, (2.34)
where θ(x, t) represents the concentration of a certain chemical at any time t in a specified
region R. If the movement of the chemical is constant throughout the region, α from (2.23)
is assumed to be a positive constant. In order to approximate the solution of equation (2.1),
a network of grid points is created throughout the rectangular region [41],
R = {(x, t)0 ≤ x ≤ L, 0 ≤ t ≤ T}, (2.35)
as shown in Figure 2.3. The region R is partitioned by dividing the interval [0, L]into n
equal parts , each having length h = L/n. Similarly the interval [0, T ] is divided into m
equal subintervals such that each of them is of length k = T/m. The corresponding points
of the intervals are denoted by xi for i = 0, 1, · · · , , n and tj for j = 0, 1, · · · ,m. The
points (xi, tj) are called mesh or grid points. Mesh points are defined as xi = hi, tj = kj
for i = 0, 1, · · · , n and j = 0, 1, · · · ,m.
The approximate solution of θ(x, t) at the mesh point (xi, tj) is expressed by θ
j
i and the true




with the average of the central difference scheme at the time steps j + 1 and j and the time
derivative ∂θ
∂t
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Figure 2.3: The Region R and Mesh Points
If we let λ = α k
h2
and substitute in equation (2.36), then equation (2.36) can be written as











Equation (2.37) indicates that the solution value at any point (i, j+ 1) on the (j+ 1)th time
interval depends on the solution values at the neighbouring points on the same level and
three points on the jth time level as shown in Figure 2.3:
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2.4 Solutions of the System of Equations
Equation (2.37) results in a matrix of the form Aθj+1 = Bθj, j = 0, 1, · · · . let 2 + 2λ = Λ
and ϑ = 2− 2λ, where
A =

Λ −λ 0 0 0 0 0 0 0
−λ Λ −λ 0 0 0 . 0 0
0 −λ Λ −λ 0 0 . 0
0 0 −λ Λ −λ . . .0 0
0 0 0 −λ Λ −λ 0 0
0 0 0 0 −λ Λ −λ. . .0
. . . . . . . . .
. . . . . . . . .
0 0 . . . . −λ Λ −λ






ϑ λ 0 0 0 0 0 0 0
λ ϑ λ 0 0 0 . 0 0
0 λ ϑ λ 0 0 . 0
0 0 λ ϑ λ . . .0 0
0 0 0 λ ϑ λ 0 0
0 0 0 0 λ ϑ λ. . .0
. . . . . . . . .
. . . . . . . . .
0 0 . . . . .λ ϑ λ
0 0 0 . . . . .λ ϑ.

(2.39)
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Definition 1
Consider m and n to be two positive integers. We call a matrix A, having m rows and n
columns, with elements on a vector space over the numerical field C, is a set of mn scalars
aij ∈ K with i = 1, · · · ,m and j = 1, · · · , n, K can be the set of real or complex numbers
which can be written as A ∈ Rm×n or A ∈ Cm×n respectively to specify the field for A. A
square matrix is an m× n with m = n. A matrix A can be abbreviated as A = (aij).
The index i is called the row index, and j is the column index. Then set ai1, ai2, · · · , ain
is called the i-th row of A and (a11, a22 · · · , ann) is called the main diagonal [42].
Definition 2
An identity matrix I is an n× n matrix such that AI = IA = A for all square matrices A
[42].
Definition 3
A square matrix A of order n is invertible, if there exist a square matrix B of order n such
that AB = BA = I . Where B is called the inverse matrix of A and is denoted by A−1
[42].
Definition 4
If A is inevitable its inverse is also invertible, that is (A−1)−1 = A [42].
Definition 5
The transpose of an m × n matrix A is denoted by AT , and is obtained by exchanging the
rows of A with the columns of A [42].
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Definition 6
A matrix A ∈ Cn is positive definite in Cn if the number (Ax, x) is real and positive for all
values of x element of complex numbers and x 6= 0 [42].
Definition 7




|aij|, i = 1, · · · , n, (2.40)




|aji|, i = 1, · · · , n. (2.41)
Matrix A is said to be strictly diagonally dominant if is diagonally dominant by both rows
and column [42].
Definition 8
(i) If A and B are two matrices of order n×m, then the sum of A and B is an n×m matrix
[41]. (ii) If A and B are two matrices of order n×m and λ a real number, then the product
of λ and A is the n×m matrix C = λA [41].
According to the definitions given above, the tridiagonal matrix A that emanated from
equation (2.37) is positive definite and strictly diagonally dominant. As a result A is in-
vertible and the equation (2.37) can be solved using standard methods of solving system
of equations or by using Matlab. To solve the systems of equation Ax = B using Matlab,
then the value of x can be expressed as x = A−1B as is used in this dissertation to solve all
system of equations.
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2.4.1 Numerical Integration:The Trapezoidal Rule
Functions that cannot be directly integrated by analytical methods can be accommodated
by numerical methods of integration, which in turn can be evaluated using calculators or
computers. In this dissertation, we use the trapezoidal rule, which is then simulated by a
computer. The trapezoidal rule gives an approximate value of a definite integral, using the
area below the curve. It approximate the areas as a set of inscribed trapezoids. This use of
trapezoids reduces the error and provides better approximations [43, 44].
2.5 Summary
Many equations involving diffusion results in non linear partial differential equations(PDEs)
as is the case in this dissertation. These PDEs can be hyperbolic, parabolic or elliptic. To
solve them, analytical or numerical methods can be applied depending on equations com-
plexity. The finite difference method is one of the numerical methods that can be applied
according to the explicit, implicit or the Crank- Nicolson approaches. The method that is
applied in this dissertation is the Crank Nicolson scheme, which has proved its self to be
more valid and stable.
The chapter that follows will present a mathematical model for the process of angiogenesis,
show application of the Crank-Nicolson method to formulate a system of equations from
the model which are then simulated using Matlab.
Chapter 3
Mathematical Model of Angiogenesis
During Tumour Development
3.1 Introduction
In Chapter 1 the stages and processes in cancer tumour development were outlined. The
critical process of angiogenesis, whereby a tumour becomes vascularised and is then termed
malignant, was highlighted. Angiogenesis is initiated when a tumour releases a diffusible
tumour angiogenic factors into surrounding tissues (the extra cellular matrix), which even-
tually reach nearby blood vessels. These factors allow degradation of the basement mem-
brane lining the blood vessels, thereby releasing endothelial cells from the lining. As the
endothelial cells are stimulated to follow the chemical gradient of tumour angiogenic fac-
tors so they migrate towards the tumour until they form capilliary sprouts which eventually
penetrate it. This chemotatic response to the tumour angiogenic factors secreted by a tu-
mour, is also enhanced by fibronectin, which is secreted by the endothelial cells.
We consider a situation in which a localised tumour triggers an angiogenic response from
a neighbouring blood vessel. The process can be modelled in terms of concentration of
33
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tumour angiogenic factors, endothelial cell density and the concentration of fibronectin.
Fick′s law is used to model the diffusion of the tumour angiogenic factors, which creates
the concentration gradient.
Models developed in this dissertation are related to previously published models which
were discussed in Chapter 1. To solve the algebraic equations comprising the new models,
the Crank-Nicolson scheme, discussed in Chapter 2, will be used; particularly in relation
to the approximations for each time interval.
This chapter will be presented as follows. Firstly molecular movement of endothelial cells
commonly known as cell flux will be discussed. Next the conservation equations for en-
dothelial cells, tumour angiogenic factors and fibronectin will be formulated. Then the
Crank-Nicholson method will be used to solve them. At the end simulated results of sys-
tems of non linear equations will be presented.
3.2 Cell Flux
When formulating equations that model endothelial cell development, including authors
like Anderson and Chaplain [11] and Holmes and Sleeman [29] consider the cell flux. Cell
flux is a term used to describe the movement of endothelial cells. Some authors consider
two factors which influence the cellular movement. These are first diffusion, which is the
random molecular movement of chemicals, and then chemotaxis, which is a directional
movement of cells along a chemical gradient [30]. However other authors also consider
the third factor which is haptotaxis. Haptotaxis is thus, the motion of endothelial cells,
from the basement membrane of a blood vessel at or the near the capillary sprout until they
reaches the tumour, is governed by homogenous random molecular diffusion, chemotaxis in
response to tumour angiogenic factors and haptotaxis in response to the fibronectin gradient
[11, 29]
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In this dissertation we will derive the total cell flux through on spatial position x during time
t. A(x, t) represents a tumour angiogenic factor concentration in spatial position x at time
t. Similarly, f(x, t) and E(x, t) will represents fibronectin and endothelial concentration
respectively in spatial position x at time t on spatial position x to derive the total cell flux
on spatial position x during time t [11, 29, 45, 46]. Following the work of Anderson and
Chaplain [11] and Edelstein-Keshet [47], we formulated an equation governing the total
cell flux as follows:
ETotal = ERandom + EChemo + EHapto, (3.1)
where ETotal represents the total collection of endothelial cells present, ERandom repre-
sents endothelial cells due to random diffusion, EChemo represents endothelial cells due
to chemotaxis, EHapto represent cells due to haptostaxis. The random flux is given as
ERandom = −DE∇E, (3.2)
where DE represents a cell random positive constant and ∇E is the rate of change of the
concentration of of endothelial cells. The chemotatic flux is given by:
EChemo = χ(E)× E∇A, (3.3)
where χ(E) is the term for chemotatic function. E is a term for endothelial cells and ∇E
is the rate of change of tumour angiogenic factors. Following a receptor kinetic law, the





where χ0 is the chemotatic coefficient and K1 is a positive constant. The haptotatic flux
can also be defined as follows:
EHapto = ρ1E∇(f), (3.5)
where ρ1 is a positive constant called the haptotatic coefficient and ∇(f) is the rate of
change of fibronection concentration. By substituting Equations (3.2), (3.3), (3.4) and (3.5)
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into (3.1) we get the equation for the total cell flux as:
ETotal = −DE∇E + χ(E)E∇A+ ρ1E∇(f). (3.6)
.
3.3 Conservation Equation for Endothelial Cells
The models discussed in Chapter 1 are incomplete incomplete because the equations gov-
erning density of endothelial cells do not include all relevant terms. For instance Anderson
and Chaplain [11] did not include a term for proliferation, Eloundou [30] did not include
the term for haptotaxis, and Holmes and Sleeman [29] did not include a term for cells lost
due to decay. As a result the model that is developed in this dissertation follows one gener-
ated by McDougall et al. [46] while also incorporating work by other authors. We assume
endothelial cells moves due to proliferation and are depleted due to decay. Thus the equa-
tion governing the rate of change of endothelial cells concentration in an arbitrary region
can be represented as:
∂tE = −∇2ETotal + F (E)G(A)−H(E), (3.7)
where F (E) and H(E) stands for the growth and loss of cells respectively and G(A) is the
equation for mitotic growth.
The term for logistic growth can be expressed as follows:
F (E) = ρ2E (1− E/E0) , (3.8)
where ρ2 is a positive constant related to the maximum mitotic rate E0 and is the maximum
amount of endothelial cells that can be carried within the specified boundary.
The growth of endothelial cells is influenced by two processes. At first endothelial cells
respond chemotatically to tumour angiogenic factors, then later proliferation takes place.
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It is assumed that until tumour angiogenic factors reach a certain threshold concentration
level of A∗ no proliferation takes place. Thus proliferation only occurs once the level of A
is bigger than the level of A∗ . This means that if the level of tumour angiogenic factors are
below the threshold level proliferation does not occur. It only takes place when the level
of tumour angiogenic factors are above the threshold. Taking G(A) as a non decreasing
function, it can be expressed as:
G(A) =

0 if A ≤ A∗,
A−A∗
A0
if A > A∗
, (3.9)
where A0 is the maximum constant value of tumour angiogenic factors at the boundary of
the tumour.
The function of cell loss is as follows:
H(E) = µE, (3.10)
where µ is a positive constant related to maximum loss rate. It can be concluded that the
rate of increase of endothelial cell concentration can be written as follows: if A ≤ A∗ no
proliferation will take place and




but if A > A∗ mitosis will take place and













for A∗ ≤ A0.
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3.4 Conservation Equation for Tumour Angiogenic Fac-
tors
The critical role played by tumour angiogenic factors in degrading the blood vessel base-
ment membrane, and so releasing endothelial cells. The equation that will be presented in
this dissertation for tumour angiogenic factors is based on previously published models of
Anderson and Chaplain [11], Eleondou [30] and Holmes and Sleeman [29]. We assume
that the tumour angiogenic factors diffuses, depletes and decays. Thus the rate of change
of tumour angiogenic factors concentration in a particular region can be represented by:
∂tA = DA∇2A− f(A)g(E)− h(A), (3.13)
where DA, is tumour angiogenic factors diffusion coefficient.
The function f(A) represents the local uptake of tumour angiogenic factor by endothelial





where Kmax is the Michaelis–Menten kinetic law constant which is equivalent to the con-
centration of tumour angiogenic factors required to achieve a reaction rate of Q/2, where
Q is maximum reaction uptake rate.
The function g(E) is a strongly increasing function which can be expressed as g(E) =
E/E0, where E0 is the maximum amount of endothelial cells that can use the tumour
angiogenic factors within the specified boundary with zero flux boundary condition. h(A)
is the decay rate for tumour angiogenic factors which are taken as:
h(A) = dA (3.15)
where d is the tumour angiogenic factors decay rate. The rate of change of the tumour
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3.5 Conservation Equation for Fibronectin
Endothelial cells secrete fibronectin which helps them adhere together. This dissertation
makes use of the conservation equation for fibronectin in an arbitrary region, as formulated
by Holmes and Sleeman [29]. We assume that the equation governing the rate of change of
fibronectin concentration has terms for: diffusion, secretion by endothelial cells, loss due
to cell-cell adhesion and loss due to decay. Thus it can be expressed as follows:
∂tf = Df∇2f +
αfEf
β + f
− sfEf − λff, (3.17)
where αf is the secretion rate, β is a positive constant, sf is the uptake rate of fibronectin
by endothelial cells and λf is the decay rate of fibronectin. The term
αfEf
β+f
represents the concentration of fibronectin which is secreted by endothelial cells. Models
already developed do not consider concentration of oxygen and glucose because as Ward
and King [2] suggest it can be neglected in the interior of larger spheroids.
3.6 Numerical Solution in one Space Dimension
The systems of equations shown in Equations (3.12), (3.16) and (3.17) are all non linear
parabolic differential equations. They are one space dimensional, because x is the only
independent spatial variable involved [35]. Solving them requires that they are first non-
dimensionalized as in Holmes and Sleeman [29]. The distance from the parent blood vessel
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to tumour is given to be L is, and the time τ = L
2
DA
, and by setting appropriate reference
variables. Accordingly, we obtain : A = A
A0
; E = E
E0
; x = x
L
; t = t
τ
; f = f
f0
, We also
let: ω = TQ
A0
; γ = km
A0
; σ = Td
A0





; η = TSfE0; κ = λfT ; ψ =
µT ; ρ = ρ1TA0
L2













Dropping the bars, the following non-dimensionalized systems are obtained from (3.16),








































+ ρ0E(1− E)G(A)− ψE. (3.20)
3.6.1 Application of the Crank-Nicolson Method in the Model for Fi-
bronectin
When solving equation (3.18) using the Crank-Nicolson scheme it becomes:



































, Cji = ∆tηE
j
i and R =
∆tκ
2
, and substituting for
P,Hji , C
j
i and R equation (3.21) will be:
f j+1i −f
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Let 1 + 2P +R = %0 and (%1)
j




i +R. After equation (3.6.1) we then
obtain a tridiagonal matrix like this for j = 0, 1, 2.....n

%0 −P 0 0 0 0
−P %0 −P . 0 0
0 −P %0 −P . 0
0 0 −P %0 −P . 0
0 0 −P %0 −P 0
0 0 −P %0 −P 0
. . . . . .
. . . . . .
0 . . −P %0 −P






























i P . . 0 0
P %1 P . . 0
0 P (%1)
j
i P . 0
0 0 P (%1)
j
i P 0
. . . . . .
. . . . . .
0 . . P (%1)
j
i P






































3.6.2 Application of the Crank-Nicolson Method in The Model for Tu-
mour Angiogenic Factors
As in the previous section, the solution of equation (3.19) is obtained by applying the
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By letting B = ∆tdA
2∆x2
, D = ∆tσ
2
, Xji = ∆t
ωEji
γ+Aji









































Let υ0 = 1 + 2B +D and (υ1)
j
i = 1− 2B −X
j
i +D For j = 0, 1, 2.....n, Equation (3.27)
can be written as a tridiagonal matrix, like shown below:

υ0 −B 0 0 0 0 . 0
−B υ0 −B 0 0 . 0 0
0 −B υ0 −B 0 0 0 0
0 0 −B υ0 −B 0 0 0
0 0 0 −B υ0 −B 0 0
. . . . . . . .
. . . . . . . .
. . . . −B υ0 −B 0
0 0 . . 0 −B υ0 −B




























i B 0 0 0 0 0 0
B (υ1)
j
i B 0 0 . . 0
0 B (υ1)
j
i B 0 0 . 0
0 0 B (υ1)
j
i B 0 . 0
0 0 0 B (υ1)
j
i B . 0
. . . . . . . .
. . . . . . . .
. . . . B (υ1)
j
i B 0
0 0 0 . . B (υ1)
j
i B







































3.6.3 Application of the Crank-Nicolson Method in The Model for En-
dothelial Cells












+ ρ0E(1− E)G(A)− ψE. (3.28)
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Dividing by A∗ Equation (3.30) gives
G(A) =














































































+ Eji − ρ


































































































i , Z, and W
j


















































Let ψ0 = (1 + 2Q + Z), (ψ1)
j

















i + Z), (ψ4)
j




i ) and (ψ5)
j


























After substituting for for j = 0, 1, 2.....n in equation (3.34) then we got system of linear
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3.7 Results and Discussion
Matrices (3.25), (3.28) and (3.35), were solved numerically using Matlab software. Pa-
rameter values, boundary and initial conditions are taken from published literature, and the
results obtained are discussed below.
3.7.1 Length Scale
We denoted L to be the distance between the blood vessel and the tumour. Holmes and
Sleeman [29] stated that if the distance between the tumour and a neighbouring blood
vessel was beyond a critical distance of 2.5 mm , then the tumour angiogenic factor failed
to stimulate the basement membrane lining the blood the vessel. Hence, they took 2, 5mm
as their reference length scale. Anderson et al. [17], vary their reference length between
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0.1 mm and 2 mm. The reference length scale in this dissertation is assumed to vary from
1 mm to 2 mm as suggested by Anderson et al. [17] .
3.7.2 Time Scale
In this dissertation T represents the time taken by endothelial cells to move from the blood
vessel to the tumour. Holmes and Sleeman [29] used 48 hours as the reference time scale
in their model whereas Anderson and Chaplain [11] chose 14 days. In this dissertation T
is chosen to be 10 days which is within the range of reference time scales cited, that is
between 2 days to 14 days.
3.7.3 The Concentration of Tumour Angiogenic Factor During Angio-
genesis
In this section we present initial conditions, boundary conditions and parametric values of
tumour angiogenic factors.
Initial and Boundary Conditions for Tumour Angiogenic Factor
The initial condition that will be used in this dissertation are derived from those given by
Holmes and Sleeman [29]and Eleondou [30]. For 0 < x < L; 0 < t < L, A(x, 0) =
10 − x2, A(L, t) = 0, A(0, t) = A0 and ∇A = 0. To be more specific, in this dissertation
the initial condition for the concentration of the tumour angiogenic factor are as follows:
A(x, 0) = 10− (i− 1)dx2 for i = 1, · · · , n, where n is the number of space steps and dx
is the length scale, which is the number of space steps and A(0, 1) = 10. The boundary
conditions are then A(0, j) = 10 and A(n, j) = 0 for j = 0, · · · , k with zero flux
boundary conditions.
Section 3.7. Results and Discussion Page 47
Figure 3.1 displays the boundary conditions of tumour angiogenic factors before angiogen-
esis. The figure illustrates that concentration of tumour angiogenic factors is maximum at
the boundary of the tumour and it decreases with increasing distance between the tumour
and blood vessel it is zero at the boundary of the blood vessel.
Figure 3.1: Plot of Initial and Boundary Values for the Concentration of Tumour Angio-
genic Factors
Parameter Values for Tumour Angiogenic Factors
Holmes and Sleeman [29] stated that the value for the non- dimensionalized tumour an-
giogenic factors diffusion coefficient, dA ranges from 9.0 × 10−2 to 1.6 × 10. Anderson
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and Chaplain [11] used a dimensional value of 2.9× 10−7cm2s−1 for their simulation. The
non-dimensionalized value for dA used in this study is 4.55 × 10−2 which is close to the
value used by Holmes and Sleeman [29].
Holmes and Sleeman [29] estimated the tumour angiogenic factors decay rate, to be be-
tween 2.7 × 10−3 and 2.7 × 10−1 but in this study it has been kept to 2.7 × 10−3 as used
by Holmes and Sleeman [29]. The chosen value for Q, the tumour angiogenic factors max-
imum reaction rate chosen is 1.0 and km, Michaelis– Mentes Kinetic law constant is 0.1.
Appendix 2 at the end indicates non-dimensional parametric values that are used in this
study.
Results for Tumour Angiogenic Factors
Matrix (3.28) generated earlier in this chapter was then converted to matlab codes, follow-
ing previously published approaches [41, 48] for generating Matlab codes.
Accordingly Figure 3.2 illustrates the concentration of tumour angiogenic factors in the
space between the tumour and blood vessel during angiogenesis specifically at 1, 3, 7, 9
and 10 days from the start. In this dissertation we assume the angiogenesis process is
completed after 10 days. Results indicate that the concentration of tumour angiogenic
factor in the space between the tumour and blood vessel at different times. Results indicate
that as time progresses, that is as the value of t increases, the level of tumour angiogenic
factors decreases. This would occur because some of the tumour angiogenic factors was
used to degrade the basement membrane on the blood vessel and other chemical is lost due
to decay.
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Figure 3.2: Spatial Distribution of the Concentration of Tumour Angiogenic Factors at
Different Times
3.7.4 Results for the Concentration of Fibronectin During Angiogen-
esis
This section shows the initial conditions, boundary conditions and parametric values of
fibronectin that are used for simulation.
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Initial and Boundary Conditions for Fibronectin
Because fibronectin is secreted by the endothelial cells there is a strong relationship be-
tween the endothelial cell profile and the fibronectin distribution. An initial condition is
imposed as used in Orme and Chaplain [12] of f(x, 0) = 0.5E(x, 0). Then f(x, 0) = 0
elsewhere in the domain.
The zero- flux boundary condition is ∇f = 0, at x = 0 and at x = L and for t in [0, T ].
For simulation in this dissertation the initial condition is taken as:
f(x, 0) =

0 if x ≤ n,
5 else where in the domain
, (3.36)
and boundary conditions were as follows: f(0, j) and f(n, j) = 5 for j = 0 · · · k with zero
flux boundary conditions as illustrated in Figure 3.3. Figure 3.3 shows the boundary condi-
tions of fibronectin before angiogenesis takes place. The figure indicates the concentration
of fibronectin to be maximum at the boundary of the blood vessel and zero elsewhere in the
domain region.
Parametric Values for Fibronectin
Holmes and Sleeman [29] stated that the value for the non-dimensional fibronectin diffu-
sion constant, df may vary from 2.7 × 10−2 to 2.7 and in this dissertation the value used
for df is chosen randomly as 2.7 × 10−2 which falls within the range given by Holmes
and Sleeman [29]. Non-dimensionalized values chosen for fibronectin secretion, uptake
rate and decay rate are 2.0 × 10−2 , 3.9 × 10−2 and 5.4 × 10−2 respectively as shown in
Appendix 2. These chosen values are in line with parametric values whi ch were used by
Holmes and Sleeman [29] as follows,for the secretion rate α, the uptake rate is §f and the
decay rate λf were 2.0× 10−2 to 2.0× 10, 5.2× 10−3 to 3.9 and 2.7× 10−3 to 2.6× 10−1
respectively.
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Figure 3.3: Plot of Initial and Boundary Conditions of Fibronectin
Results Simulated for Fibronectin Concentration
Matrix (3.25) generated earlier in this chapter was then converted to matlab codes, follow-
ing previously published approaches [41, 48] for generating Matlab codes.
Figure 3.4 illustrates the concentration of fibronectin in the region during different times
of angiogenesis; that is 1, 3, 5, 7, 9, and 10 days. The graphs indicates that, fibronectin
behaved in the same way as endothelial cells. Graphs indicate that as time progresses,
fibronectin concentration decreases with distance away from the blood vessel.
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Figure 3.4: A Plot Showing Spatial Distribution of Fibronectin concentration at Different
Times
3.7.5 The Concentration of Endothelial Cells During Angiogenesis
This section reports the initial conditions, boundary conditions and parametric values that
will be used to simulate the concentration of endothelial cells in this dissertation.
Initial and Boundary Condition for Endothelial Cells
The initial conditions that will be used in this dissertation are in line with those used by
Holmes and Sleeman [29] and Eleondou [30]. The initial condition for endothelial cells in
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this dissertation for 0 < x < L and 0 < t < T is :
E(x, 0) =

0 if x < L, j ≤ n
10 else where in the domain
, j = n+ 1. (3.37)
The boundary conditions were as follows: E(0, j) = 0 and E(L, j) = 10 for j =
0, · · · , k with zero flux boundary conditions, which means that ∇E = 0, at x = 0 and
at x = L Figure 3.5 indicates the boundary conditions of endothelial cells before angio-
Figure 3.5: Plot of Initial and Boundary Conditions of Endothelial cells
genesis. The figure illustrates that the concentration of endothelial cell is maximum at the
boundary of the blood vessel and is zero at the boundary of the tumour.
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Parametric Values for Endothelial Cells
Anderson and Chaplain [11] on the other hand use the non-dimensionalized value for en-
dothelial diffusion constant dE to be equal to 3.5 × 10−4 while Holmes and Sleeman [29]
on the other hand choose a range from 2.8× 10−4 − 2.8× 10−2. Eleondou [30] also used
3.5 × 10−10 cm2 s−1for the dimensionalized value of dE . Other parametric values values
used by Holmes and Sleeman [29] are given in Table 3.1 Parameters which are used in
Table 3.1: Parametric Values Used by Holmes and Sleeman
chemotaxis positive constant χ1 3.5× 10−4 − 4.8× 10−1
maximum decay rate of EC ψ 6.94× 10−6
haptotaxis coefficient t ρ1 2.8× 10−6 − 3.9× 10
mitotic coefficient ρ2 9.5− 2.7× 10
this dissertation for the migration of endothelial cells are in Table 3.2 and they are in line
with parametric values as used by Holmes and Sleeman [29] Other parameters appear on
Table 3.2: Non-dimemsionalized Parametric Values for Endothelial Cells that are used in
the Dissertation
endothelial diffusion constant dE 2.8× 10−3
endothelial positive constant K1 1
haptotaxis coefficient ρ1 4.8× 10−5
decay rate ψ 9.4× 10−7
chemotaxis positive constant χ1 3.5× 10−5
Appendix 2 at the end of this dissertation and were were randomly.
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Results for Endothelial Cells
Matrix (3.35) generated earlier in this chapter was then converted to Matlab codes, fol-
lowing previously published approaches [41, 48] for generating Matlab codes. Figure 3.6
illustrates the concentration of fibronectin in the region during these different times of an-
giogenesis; 1, 3, 5, 7, 9 and 10 days.
Figure 3.6: A Plot of the Concentration of Endothelial Cells at Different Times
Results indicate that the endothelial cells escape from the blood vessel and they migrate to-
wards the tumour. It is noticed that as time progresses the distance between the endothelial
cells and the tumour decreases until and they eventually reach the tumour. In this way they
complete the process of angiogenesis. Figure 3.6 indicates that endothelial cells reach the
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tumour after 10 days, which is in accordance with the assumption given at the beginning of
this chapter.
3.8 Summary
Parabolic equations governing the conservation of tumour angiogenic factors, fibronectin
and endothelial cells have been developed. A finite method, the Crank- Nicolson method,
is applied to solve them. The matrices acquired are then simulated with the aid of Matlab,
using parametric values already published or those chosen to suit this study. The results
indicate the concentration of tumour angiogenic factors is greater near the tumour bound-
ary, but shifts towards the blood vessel as time progresses. At the same time fibronectin
and endothelial cells are also observed to migrate towards the tumour, and eventually reach
it. That indicates that angiogenesis is the process of transition for the tumour from being
avascular to become vascular. As such this confirms that our model is reasonable.
The next chapter will demonstrate the role of the anti-angiogenic factor in angiogenesis,
when the relevant terms will be added to the system of equations. The equations in the new




In this chapter we consider a situation in which anti-angiogenesis treatment is administered
before a tumour is vascularized. The process of anti-angiogenesis was described in the
literature review in Chapter 1. It occurs as the primary tumour secrets an anti-angiogenic
factors, which impedes secondary tumour growth, by preventing vascularization. Thus
anti-angiogenesis can also be harnessed as a treatment for cancer. As was pointed out
in Chapter 1, the work in this dissertation will strengthen the existing models for tumour
growth by including terms for the process of anti-angiogenesis. This will be effected by
applying the dose dependent method, wherein an anti-angiogenic factors will be added to
the equation for endothelial cells concentration and results will be generated by simulation.
New models that will be presented in this chapter are for the anti-angigenic factors and the
conservation of endothelial cells being the aspects that influence and are a response to the
treatment. Models for tumour angiogenic factors and for fibronectin will be used as they
were in Chapter 3.
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4.2 Mathematical Model for Anti-Angiogenic Factors
The equation governing the conservation of the tumour will be used from Chapter 3 as
follows:
∂tA = DA∇2A− f(A)g(E)− h(A). (4.1)
The equation governing fibronectin will also be used as it appears in Chapter 3 which
mathematically is expressed as:
∂tf = Df∇2f +
αfEf
β + f
− sfEf − λff. (4.2)
The anti-angiogenic factor is the treatment administered in this dissertation. It will be added
to the region of interest, and then its conservation equation will be based on diffusion,
uptake of the factor by endothelial cells and its loss due to decay as had been assumed with










where λ1 represents the decay rate, ς is the anti-angiogenesis factor reaction rate and K0 is
anti-angiogenic factors reaction constant.
4.3 The Mathematical Model for Endothelial Cells During
Treatment
As was noted in Chapter 1, biological experiments and mathematical models complement
each other. In particular, this work builds on the empirical and theoretical work reported by
Anderson et al. [17] and Folkman [13], as was outlined in Chapter 1. The model formulated
by Anderson et al. [17] for an equation governing the concentration of endothelial cells
during anti-angiogenesis considers the roles of neither haptotaxis nor mitosis in migration
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of endothelial cells towards a tumour. They also assume that the function for angiostatin,
follow a simple linear form.
In this dissertation the model to govern the development of endothelial cells during anti-
angiogenesis is based on diffusion, the chemotatic effect by the tumour angiogenetic fac-
tors, endothelial cell-cell adherence through fibronection, cell mitosis, the chemotatic ef-
fect by anti-angiogenic factors and endothelial cell lost due to decay. In this dissertation
it is assumed that the function describing conservation of anti-angiogenic factors follows
a simple logistic form just like the funtion for tumour angiogenic factors. The function
for anti-angiogenic factors is as follows: α(a) = α0a K0(K0+a) , where α0 (a positive constant
coefficient) is the anti-angiogenic chemotatic factor indicting strength of the chemotactic
response due to angiostatin and K0 is also positive constant of the desensitisation of en-
dothelial cell due to anti-angiogenic factors. When the term for the anti-angiogenic factor

























The anti-angiogenic factor concentration satisfies the following boundary conditions:
a = am, x = L, a = 0 and x = 0.
We note that the concentration of anti-angiogenic factor at the blood vessel varies depend-
ing on the dose applied. The dose that is added to the region during each time interval is
given by: ak for 0 ≤ k ≤ t.
4.4 Numerical Solution in One Space Dimension
To solve Equation (4.4), which is a nonlinear parabolic differential equation, the implicit
finite difference method of Crank-Nicolson will be used, as was applied in Chapter 3.
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4.4.1 Non-dimensionalizing
Equation (4.4) is non-dimensionalized by rescaling the distance between the blood ves-
sel and the tumour with L, time with τ = L
2
DA
, (where DA, is the tumour angiogenic
factor diffusion coefficient), endothelial cell density with E0, and tumour angiogenetic fac-
tors and anti-angiogenesis concentrations with A0 and a0, respectively where A0 is the





, λ = Tλ1
L2






































4.5 Solution for the Anti-angiogenic Factor
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where g = ∆tda
2∆x2



































On rearranging terms, equation (4.9) then becomes:








i+1 + (1− 2g+h+m
j
i )a
ji + gaji . (4.10)






i , then the above equation can be written
in a tridiagonal form, that is;

ρa −g 0 0 0 0 0 0
−g ρa −g 0 0 . . 0
0 −g ρa −g 0 0 . .
0 0 −g ρa −g 0 . .
0 0 0 −g ρa −g . .
. . . . . . . .
0 . . . . −g ρa −g
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g (ρb)
j
i g 0 0 0 . 0
0 g (ρb)
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i g 0 0 . 0
0 g (ρb)
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4.6 Solution of the Model for Endothelial Cells Conserva-
tion during Anti-angiogenesis





























Section 4.6. Solution of the Model for Endothelial Cells Conservation during Anti-angiogenesisPage 62







































































































































































































































































Section 4.7. Model Solution for Anti-angiogenesis Page 63































































Rearranging terms equation (4.13) then becomes:






i+1 + (1 + 2Q+ Z)e
j+1
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4.7 Model Solution for Anti-angiogenesis
In this section we show results for the concentration of the endothelial cells when the anti-
angiogenic factor is added to the equation, to model would happen with treatment. Results
are obtained from a simulation.
The process of angiogenesis is assumed to take 10 days. Results are shown for endothelial
cells concentration as anti-angiogenic factors is added to the equation for endothelial cells
during angiogenesis.
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4.7.1 Results Illustrating the Concentration of Tumour Angiogenic
Factor during Anti-angiogenesis
In the simulation, the anti-angiogenic factor is added 3 days after when the process of
angiogenesis started, which had been taken at t = 0. Results are then generated for t =
3, 5, 7 and 10 days after angiogenesis. These values were chosen randomly. Parametric
values for the model governing the tumour angiogenic factor are the same as those used in
Chapter 3. The results are shown in
Figure 4.1: Plot of the Concentration of Tumour Angiogenic Factor After Application of
Anti-angiogenic Factor
The graph in Figure 4.1 shows that after the addition of anti-angiogenic factors although
the concentration of the tumour angiogenic factor decreases,it remains above zero. This
means that the tumour angiogenic factor is available for degrading the basement membrane
of the blood vessel so as to allow the migration of endothelial cells as was discussed in
Chapter 3.
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4.7.2 Results Showing the Concentration of Fibronectin during Anti-
angiogenesis
Parametric values for fibronectin are the same as those used in Chapter 3. The results of the
simulation are shown in Figure 4.2. Results indicate that as time increases the fibronectin
Figure 4.2: Plot of Fibronectin Concentration After Application of Anti-angiogenic Factor
concentration increases by a a small amount over its value during initial stages of no treat-
ment. Fibronectin is therefore still being produced in the region. Because endothelial cells
are the source of fibronectin, this therefore indicates that they are still present in the arbi-
trary region.
The concentration of fibronectin was calculated using trapezodial rule. Near the start of
the treatment, 3 days after angiogenesis process had begun it was 70.06 units and after
10 days, it had increased to 86.97 units. Thus, 10 days after angiogenesis had began,
the concentration of fibronectin was much less than 151.1 units, which is the value for
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fibronectin after the same period without treatment. This shows that the treatment does not
completely stop the growth of endothelial cells, because they are the source of fibronectin.
However, the concentration of fibronectin is much reduced, which suggests that endothelial
cell concentration is also reduced.
4.7.3 Results for the Concentration of Anti-Angiogenic Factor
In this section we show initial conditions, boundary conditions and parametric values of
tumour angiogenetic factors , which are then used to provide results by simulation.
Initial and Boundary Conditions for Anti-angiogenic Factor
The initial, boundary conditions and parameters that are used in this paper are as follows:
The initial condition for the anti-angiogenetic factor, a(x, 0) is 1 through out. The boundary
conditions is set as follows: a(0, t) = 1 and a(L, t) = 1 for 0 ≤ x ≤ L; 0 ≤
t <≤ k. The initial condition for the anti-angiogenetic factor in linear form is represented
by the equation, a(x, 0) = 1 − x2 and its boundary conditions is a(0, t) = 1 and
a(L, t) = 1 with zero flux boundary conditions. The boundary conditions a(0, j) = 1 and
a(n, j) = 1 for j = 0 · · · k, where k is the maximum time interval.
Parametric Values for the Anti-Angiogenic Factor
For non dimensional angiostatin chemotactic co-efficient Anderson et al. [17] used the
value of 0.38 and they kept the anti-angiogenetic factor diffusion coefficient similar to the
diffusion coefficient for the tumour angiogenetic factor. In this paper parametric values for
the following terms were: The non-dimensional parametric values used in this dissertation
for the remaining terms are given in Table 4.1.
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Table 4.1: Parametric Values for Anti-Angiogenic Factor
anti-angigenetic factor diffusion coefficient da 1.79× 10−4
anti-angigenetic factor decay rate λ1 5.0×1 0−2
uptake rate of anti-angigenetic factor r(0) 1.0× 10−3
Maximum constant rate of anti-angigenetic factor q 3.0× 10−1
Michaelis Mentis Kinetic Constant $ 3.08× 10−1
Results Attained for Anti-Angiogenic Factor
The simulation to show the effect of changing level on the concentration of the anti-
angiogenic factor when the value K changes, are given in Figure 4.3. The figure shows
Figure 4.3: Plot of Anti-angiogenic Factor Concentration
that the concentration of anti-angiogenic factor increases as time progresses, as is shown
for the increasing values of k.
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4.7.4 Results Illustrating The Concentration of Endothelial Cells Dur-
ing Anti-angiogenesis
That density of endothelial cells when the treatment is added after 3 days are displayed in
Figure 4.4, and is taken as the initial condition for anti-angiogenesis process.
The effect of anti-angiogenic factor is investigated by observing endothelial cells behaviour
as initiated at two different stages of angiogenesis.
Figure 4.4: Plot of Endothelial Cell Concentration After Application of Anti-angiogenic
Factor After 5 Days of Angiogenesis
Treatment is also applied after 7 days, results are displayed in Figure 4.5.
The presence of fibronectin, as shown in Figure 4.2, means that endothelial cells has escape
from the basal membrane. Results in both Figure 4.4 and Figure 4.4 indicate that the
treatment start working immediately when the treatment is added. Endothelial cells present
in a region before the treatment also disappear after the treatment.
The trapezoidal rule from Matlab is also used to determine the concentration of endothelial
cells in the bounded region. From calculations using trapezoidal method it shows that
the area below the curve for both graphs during the same interval are the same. At the
beginning of the dose the endothelial cell concentration is 72.1 units and it later dropped to
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Figure 4.5: Plot of Endothelial Cells Concentration on Application of Anti-angiogenic
Factor 7 days After Angiogenesis Started
5 units after 10 days. But without a treatment the concentration level of endothelial cells
after 10 days is 162, 87 units. Results indicates that the concentration of endothelial cells
after administering the treatment becomes very low. This leads to the conclusion that the
treatment destroys endothelial cells appearing in the region .
From these observations we can therefore conclude that according to our new model, which
included anti-angiogenesis as a treatment, the treatment is effective in inhibiting and de-
stroying endothelial cells from reaching the tumour. Inhibiting angiogenesis could be a
most effective way of preventing tumours progressing to the malignant stage.
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4.8 Summary
Models governing the conservation of the anti-angiogenesis are developed. A discrete
method for solving them, the Crank Nicholson’s method is applied and the matrices so
acquired are used in simulation by Matlab. Results obtained indicate that when anti-
angiogenic term is added to the equation for endothelial cell concentration, endothelial
cells are destroyed. This has a huge implications for cancer treatment.




The process of tumour development is very complex. The change in a tumour from avas-
cular to vascular is called angiogenesis. During this process the tumour acquires its own
blood vessels, by which it then obtains nutrients, so it will no longer depends on diffusion
through the surrounding tissues for its survival.
There are three main processes in angiogenesis. It starts by tumour cells secreting tumour
angiogenic factors, which migrate towards the basal membrane lining the nearby blood
vessel. The tumour angiogenic factors then degrade the basal membrane and endothelial
cells from the nearby blood vessel start to escape and follow the chemical gradient of the
tumour angiogenic factor back to the tumour. Endothelial cells also secrete a fibronectin,
which assists in their adhering together. The movement of endothelial cells is thus governed
by diffusion, chemotaxis and haptotaxis.
Mathematical models for the process of angiogenesis are complicated and involve a number
of processes. The equation governing tumour angiogenic factor concentration indicates
that its conservation is governed by diffusion, uptake of chemical by endothelial cells,
and loss of chemical due to decay. Similarly, the model governing the conservation of
fibronectin is based on secretion of fibronectin by endothelial cells, diffusion, uptake of
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the chemical by endothelial cells, and loss of chemical due to decay. The third model for
the conservation of endothelial cells indicates that their conservation is based on diffusion,
chemotaxis, haptotaxis, logistic growth of the cells and loss due to decay.
All non linear second order partial differential equations obtained here were solved using
the Crank-Nicolson Method. All the numerical solutions presented here were produced
from a finite difference approximation of the system with boundary, initial and zero flux
boundary conditions imposed.
During angiogenesis results showed that as time progresses the concentration of tumour
angiogenetic factor decreased from the boundaries of the tumour. At the same time en-
dothelial cells migrated towards the tumour.
Then anti-angiogenic factor was introduced to the region. Initial, boundary and zero flux
boundary conditions were imposed and simulations were applied, after discretisizing the
models, using Matlab.
Results for anti-angiogenesis process showed that endothelial cells responded chemotacti-
cally to two opposing gradients, that is, the gradients of the anti-angiogenic chemical and
also the tumour angiogenic factor. The consequent cell motion is governed by the relative
strength of each. Results indicated that the anti-angiogenic factor does hinder the growth
of endothelial cells, and also destroy endothelial cells appearing in the region.
Findings also indicated that anti-angiogenic factor is the effective treatment for inhibiting
and destroying endothelial cells from reaching the tumour. Inhibiting angiogenesis could
be one of the most effective way of preventing tumours progressing to the malignant stage.
Our numerical simulations yielded results, that are in agreement with the experimental ob-
servations obtained by Anderson et al. [17], who concluded that anti-angiogenic factors
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hinders tumour growth. Results obtained here are in line with the three types of anti-
angiogenesis given by Orme and Chaplain [12] in Chapter 1. Our results indicate the ef-
fectiveness of anti-angiogenesis as a treatment to prevent vascularization of non-cancerous
tumours. Anderson et al. [17] showed that removal of a primary tumour promoted the
change of secondary tumours (possibly still benign) into malignant tumours. By adminis-
tering anti-angiogenic drugs, one could prevent this from happening.
What was challenging in this dissertation was the skill of choosing appropriate parametric
values and appropriate scales. Some Parametric values used were chosen from published
data and others were randomly selected.
Our findings could be particularized to investigate treating different types of tumour, es-
pecially those in breast cancer. In this regard, Enderlinga et al. [49] pointed out that,
currently the only treatment for it is surgical operations removal which is then followed by
radiotherapy.
Furthermore, investigations are needed concerning the best time to administer the treat-
ment, and to find out what happens to the endothelial cell proliferation if a patient discon-
tinues, or is inconsistent with the treatment. It will also be interesting to investigate the
effectiveness of the treatment in a fully vascularised tumour.
Appendix 1- Glossary
The definitions below relate to the way the terms are used in this dissertation. Page number
refer to the page of text where the definition may be found.
• anastomoses (page 4) A connection that is created between tubular structures, such as blood
vessels or loops of intestine
• angiogenesispages (i & 3) A process of tumour development from avascular to vascular stage
• angiostatin (page 7) An anti-angiogenic factor that blocks the growth of new blood vessels
• anti-angiogenesis (page 6)-The process that hinders the growth of endothelial
• anti-angiogenic factor ( 12 ) A chemical that hinders the growth of endothelial cells
• avascular (page 2 ) A stage in cancer growth where in a tumour has not developed blood or
lymphatic vessels.
• benign tumour (page 2) A non-cancerous tumour
• endothelial cells (page 3) Cells lining the interior surface of blood vessels and lymphatic vessels
• capillary sprout (page 4 ) A branching structure of at least three endothelial cells connected to
each other in a linear manner
• chemotaxis ( page 3) The movement of endothelial cells following a chemical gradient
• fibronectin (page 4 ) A glycoprotein of the extracellular matrix that binds extracellular matrix
components together
• haptotaxis (page 4 ) Cell migration along a gradient of extra cellular matrix while bound by
chemo-attractants
• malignant tumour (page 2 ) A cancerous tumour
• metastasis (page 2 ) The process of development of secondary malignant growths at a distance
from a primary site of cancer
• tumour angiogenic factor (page 4) A chemicals that are secreted by tumour which promote
tumour angiogenesis
• pre-malignant (page 2 ) A precancerous condition
• vascular (page 2) A stage in cancer growth where in a tumour has developed its own blood
vessels.
• proliferation ( 3 )- Reproducing or replicating of cells
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Appendix 2- List of keywords
Table 5.1: Parametric Values for Anti-Angiogenic Factor
AAF Anti-Angiogenetic Factor.
BV Blood Vessel.
DDM Dose Dependent Method.
EC Endothelial Cell.
ECM Extra cellullar Matrix.
PT Primary Tumour.
TAF Tumour Angiogenetic Factor.
VEGF Vascular Endothelial Growth Factor.
75
Appendix 3- List of parameters
Table 5.2: Parametric Values For Tumour Angiogenic Factor
Parameters
Description values
DA Tumour-angiogenic diffusion constant 2.5× 10−4
A0 TAF maximum value. 1.0
Q TAF maximum reaction rate. 0.33× 10−2
d TAF decay rate. 9.0× 10−7
Table 5.3: Parametric Values for Fibronectin
Parameters Description values
Df Fibronectin diffusion constant 1.733× 10−6
f0 Fibronectin maximum value. 1.0
αf Fibronection secretion rate. 6.667× 10−6
sf Fibronectin uptake rate 1.3× 10−4
ρ1 Haptotatic coefficient 1.6× 10−6
λf Fibronectin decay rate 9.0× 10−7
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Table 5.4: Parametric Values for Endothelial Cells
Parameters
Description values
DE Endothelial cell diffusion constant. 9.333× 10−5
χ0 Chemotaxis coefficient. 1.3× 10−6
E0 Endothelial cell maximum value. 1
ρ2 mitotic rate. 3.667× 10−9
µ Endothelial cell decay rate. 3.133× 10−8
K1 chemotatic positive constant. 1.0
km Michaelis Menten Kinetic law constant . 1.0
Table 5.5: Parametric Values for Anti-Angiogenic Factor
Parameters for
Anti-Angiogenesis Description values
Da Anti-angiogenic diffusion constant. 1.76× 10−4
λ1 AAF decay rate. 1.67× 10−3
ς AAF chemotatic reaction rate. 0.27× 10−5
K0 AAF chemotatic positive constant. 1.0
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